___

• 1. Bañuls AL, Sanou A, Anh NT et al. Mycobacterium tuberculosis: ecology and evolution of a human bacterium. Journal of Medical Microbiology 2015;64(11):1261-9.
• 2. Murray PR. Mikobakteri. In: Başustaoğlu AC, Yapar M, Tanyüksel M, editors. Tıbbi Mikrobiyoloji. Philadelphia: Mosby; 2014.p.277-90.
• 3. Akdağ R. Tüberküloz tanı ve tedavi rehberi. Ankara Türkiye Cumhuriyeti Sağlık Bakanlığı: 2011. 4. Menzies HJ, Moalosi G, Anisimova V et al. Increase in anti-tuberculosis drug resistance in Botswana: results from the fourth National Drug Resistance Survey. Int J Tuberc Lung Dis 2014;18(9):1026-33.
• 5. Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2:10–5.
• 6. Matteelli A, Migliori GB, Cirillo D et al. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 2007;5:857–71.
• 7. Durmaz R. Mycobacterium tuberculosisde direnç sorunu. ANKEM Derg 2005;19(2):107-10.
• 8. Perinçek G, Tabakoğlu E, Otkun M et al. The change of antituberculosis drug resistance rate in Edirne region in 1996 and 2006. Solunum 2010;12(3):129–33.
• 9. Tansel Ö, Kuluoğlu F, Akata F et al. Resistance of Mycobacterium tuberculosis isolates to antituberculous agents: results of the last two years in Trakya University Hospital. Turkish Journal of Infection 2003;17(1):23-6.
• 10. Baylan O. Extensively drug resistant and extremely drug resistant tuberculosis forms after multi-drug resistant tuberculosis: new faces of the old disease. Mikrobiyol Bul 2011;45(1):181-95.
• 11. World Health Organization. Global tuberculosis report. Available from URL: http://apps.who.int/iris/bitstream/10665/250441/1/9789241565394-eng. pdf?ua=1&ua=1 (December 2016).
• 12. World Health Organization. The end TB strategy. Available from URL: http://www.who.int/tb/strategy/End_TB_Strategy.pdf?ua=1 (04/06/2018).
• 13. Perinçek G, Tabakoğlu E, Otkun M et al. Mycobacterium tuberculosis üremesi saptanan akciğer tüberkülozlu hastaların antitüberküloz ilaçlara direnç oranları. Tur Toraks Der 2011;12:111-3.
• 14. Sayğan MB, Ocak F, Cesur S et al. Susceptibilities of Mycobacterium tuberculosis strains collected from regional tuberculosis laboratories to major antituberculous drugs. Mikrobiyol Bul 2007;41:403-9. 15. Baylan O, Kısa BÖ, Albay A et al. Mikobakteriyoloji laboratuarımızda 2002 yılında tüberküloz olgularından izole edilen Mycobacterium tuberculosis kompleks (MTC) suşları ve antitüberküloz ilaç duyarlılık sonuçları. Gülhane Tıp Dergisi 2003;45(3):256-62.
• 16. Khalid FA, Hamid ZA, Mukhtar MM. Tuberculosis drug resistance isolates from pulmonary tuberculosis patients, Kassala State, Sudan. Int J Mycobacteriol 2015;4(1):44-7.
• 17. Tavanaee Sani A, Shakiba A, Salehi M et al. Epidemiological characterization of drug resistance among Mycobacterium tuberculosis isolated from patients in northeast of Iran during 2012-2013. Biomed Res Int 2015;2015:747085.
• 18. Baylan O, Albay A, Kısa Ö et al. Detection of primary drug resistance rates of Mycobacterium tuberculosis complex strains isolated between 2002-2003 years and comparison with the data of 1998-2001 period. Mikrobiyol Bul 2005;39:153-60.
• 19. Bozdağ İ, Coşar AD, Özer A. Klinik örneklerden izole edilen Mycobacterium tuberculosis kompleks suşlarının antibiyotiklere direnç oranları. Tıp Araştırmaları Dergisi 2015;13(1):6-10.
• 20. Sezen F, Albayrak N, Özkara Ş et al. The first step for national tuberculosis laboratory surveillance; Ankara, 2011. Mikrobiyol Bul 2015;49(2):143-55.